Telos Capital Management Inc. purchased a new stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 5,555 shares of the company’s stock, valued at approximately $608,000.
Several other hedge funds and other institutional investors also recently modified their holdings of PPH. Commonwealth Equity Services LLC purchased a new stake in VanEck Pharmaceutical ETF in the third quarter worth about $1,171,000. ARQ Wealth Advisors LLC boosted its position in VanEck Pharmaceutical ETF by 7.2% during the 3rd quarter. ARQ Wealth Advisors LLC now owns 11,443 shares of the company’s stock valued at $1,253,000 after acquiring an additional 769 shares in the last quarter. North Star Investment Management Corp. bought a new stake in VanEck Pharmaceutical ETF during the 3rd quarter valued at approximately $64,000. Latitude Advisors LLC purchased a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter worth approximately $55,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter worth approximately $711,000.
VanEck Pharmaceutical ETF Stock Performance
Shares of NASDAQ:PPH opened at $119.01 on Friday. VanEck Pharmaceutical ETF has a 52-week low of $93.11 and a 52-week high of $123.53. The firm has a market capitalization of $1.14 billion, a P/E ratio of 20.21 and a beta of 0.43. The stock has a 50 day moving average price of $112.83 and a 200-day moving average price of $108.23.
VanEck Pharmaceutical ETF Cuts Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were paid a $0.36 dividend. The ex-dividend date of this dividend was Thursday, October 1st. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. This represents a $1.44 annualized dividend and a yield of 1.2%.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Recommended Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
